Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Receivables (2021 - 2025)

Historic Change in Receivables for Apellis Pharmaceuticals (APLS) over the last 5 years, with Q3 2025 value amounting to $131.4 million.

  • Apellis Pharmaceuticals' Change in Receivables rose 61690.73% to $131.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.5 million, marking a year-over-year decrease of 3938.51%. This contributed to the annual value of $58.5 million for FY2024, which is 7056.89% down from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Change in Receivables of $131.4 million as of Q3 2025, which was up 61690.73% from -$21.1 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' 5-year Change in Receivables high stood at $131.4 million for Q3 2025, and its period low was -$29.7 million during Q1 2025.
  • For the 5-year period, Apellis Pharmaceuticals' Change in Receivables averaged around $20.3 million, with its median value being $1.9 million (2021).
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Change in Receivables surged by 1028438.36% in 2023, and later tumbled by 15773.89% in 2025.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Change in Receivables stood at $7.5 million in 2021, then crashed by 104.88% to -$365000.0 in 2022, then soared by 10284.38% to $37.2 million in 2023, then tumbled by 137.89% to -$14.1 million in 2024, then soared by 1032.93% to $131.4 million in 2025.
  • Its last three reported values are $131.4 million in Q3 2025, -$21.1 million for Q2 2025, and -$29.7 million during Q1 2025.